Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemiaDavide Rossi, Gianluca Gaïdano, Lodovico Terzi-di-Bergamo et al.|Blood|2015Cited by 215
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemiaPhilipp B. Staber, Claire Dearden, Marco Herling et al.|Blood|2019Cited by 161
Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studiesWilma Barcellini, Alberto Zanella, Francesco Zaja et al.|Blood|2012Cited by 144
Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long‐term responseMiriam Marangon, Francesco Zaja, Wilma Barcellini et al.|European Journal Of Haematology|2016Cited by 90
Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA studyGiuseppe Rossi, Wilma Barcellini, Doriana Gramegna et al.|Blood|2018Cited by 89